文献速递消化系统肿瘤

转移性结直肠癌患者DNA甲基化调控基因多态性影响:来自TRIBE、MAVERICC和FIRE-3三项独立随机开放标签临床试验的荟萃分析

Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3.
PubMed 文献 · Eur J Cancer · 2019-03-07

该荟萃分析纳入TRIBE、MAVERICC和FIRE-3三项随机开放标签临床试验的884例转移性结直肠癌患者,分析DNA甲基化与去甲基化通路基因单核苷酸多态性与预后的关联。结果显示DNMT3A rs11681717与总生存显著相关(HR=1.26,95%CI 1.08-1.46,P=0.002,FDR=0.016),TET1 rs3814177和TET3 rs7560668与肿瘤缓解存在提示性关联。作者认为DNA甲基化/去甲基化机制相关基因多态性与mCRC患者结局相关,并证明荟萃分析方法可行。

要点

  • DNMT3A rs11681717与转移性结直肠癌患者总生存显著相关(HR=1.26,95%CI 1.08-1.46,P=0.002,FDR=0.016)。
  • TET1 rs3814177与肿瘤缓解存在提示性关联(OR=0.76,95%CI 0.59-0.97,P=0.025,FDR=0.087)。
  • TET3 rs7560668与肿瘤缓解存在提示性关联(OR=1.44,95%CI 1.10-1.89,P=0.009,FDR=0.062)。

核心结论

  • DNA甲基化与去甲基化机制相关基因的多态性与转移性结直肠癌患者结局相关。
  • 荟萃分析方法可识别基因多态性与结局之间更强、更可信的关联,可能为类似数据集提供新的分析途径。

研究设计与样本

  • 研究纳入TRIBE、MAVERICC和FIRE-3三项独立、随机、开放标签临床试验的884例转移性结直肠癌患者。
  • 分析DNA甲基化与去甲基化通路基因的单核苷酸多态性。
  • 采用METASOFT软件实现的逆方差加权效应量荟萃分析方法,量化每个SNP在所有治疗组中的预后价值。

主要发现

  • DNMT3A rs11681717与总生存显著相关(HR=1.26,95%CI 1.08-1.46,P=0.002,FDR=0.016),校正DNA甲基化通路7次检验。
  • TET1 rs3814177与肿瘤缓解存在提示性关联(OR=0.76,95%CI 0.59-0.97,P=0.025,FDR=0.087)。
  • TET3 rs7560668与肿瘤缓解存在提示性关联(OR=1.44,95%CI 1.10-1.89,P=0.009,FDR=0.062)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: CpG island DNA hypermethylation and global DNA hypomethylation are hallmark characteristics of colorectal cancer (CRC). Therefore, we aim to explore the effect of genetic variations within the genes that regulate the DNA methylation and demethylation pathways on outcomes in patients with metastatic CRC (mCRC) treated with first-line therapy and enrolled in three independent, randomised, open-label clinical trials. METHODS: A total of 884 patients with mCRC enrolled in TRIBE, MAVERICC and FIRE-3 trials were included. Single-nucleotide polymorphisms (SNPs) within genes involved in DNA methylation and demethylation pathways were analysed. The prognostic value of each SNP across all treatment arms was quantified using the inverse-variance-weighted effect size, a meta-analysis approach implemented in the METASOFT software. RESULTS: In the meta-analysis, DNMT3A rs11681717 was significantly associated with overall survival (hazard ratio = 1.26; 95% confidence interval [CI] 1.08-1.46; P = 0.002; false discovery rate [FDR] = 0.016), accounting for seven tests in the DNA methylation pathway. In addition, there was suggestive evidence of association for ten-eleven translocation (TET) genes variance with tumour response (TET1 rs3814177, odds ratio [OR] = 0.76, 95% CI 0.59-0.97, P = 0.025, FDR = 0.087; TET3 rs7560668, OR = 1.44; 95% CI 1.10-1.89; P = 0.009; FDR = 0.062). CONCLUSIONS: We showed that polymorphisms within the genes responsible for the DNA methylation and demethylation machineries are correlated with outcomes in patients with mCRC who were enrolled in three independent, randomised, open-label, phase II/III clinical trials. In addition, we demonstrated the feasibility of a meta-analysis approach to identify stronger and more convincing association between gene polymorphisms and outcome, potentially leading the way to a new method of analysis for similar data set.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Puccini A, Loupakis F, Stintzing S, et al. Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3. Eur J Cancer. 2019. PMID: 30852420. doi:10.1016/j.ejca.2019.01.105

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。